Related Experiment Video

Updated: Apr 27, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

8.4K

Increased plasma DPP4 activities predict new-onset atherosclerosis in association with its proinflammatory effects in

T P Zheng1, F Yang1, Y Gao2

  • 1Department of Endocrinology and Metabolism, Affiliated Hospital of Guilin Medical University, Guangxi, PR China.

Atherosclerosis
|June 27, 2014
PubMed
Abstract

Insights

Elevated dipeptidyl peptidase-4 (DPP4) activity predicts new-onset inflammation and atherosclerosis in Chinese adults. Higher DPP4 levels were associated with increased risk of developing atherosclerosis over a four-year period.

Area of Science:

  • Cardiovascular Research
  • Inflammation Biology
  • Metabolic Syndrome

Background:

  • Dipeptidyl peptidase-4 (DPP4) is a proinflammatory cytokine implicated in inflammatory processes via interaction with the IGF-II/M6P receptor.
  • Atherosclerosis is a significant health concern, and identifying novel predictive markers is crucial for early intervention.

Purpose of the Study:

  • To investigate the predictive value of DPP4 activity for new-onset atherosclerosis in a Chinese population.
  • To explore the association between DPP4 activity, inflammatory markers, and atherosclerosis development.

Main Methods:

  • A prospective study involving 590 Chinese adults (aged 18-70) without atherosclerosis at baseline.
  • Measurement of circulating DPP4 activity, inflammatory markers, IGF-II/M6P receptor, and common carotid artery intima-media thickness (C-IMT) at baseline and after a 4-year follow-up.

Main Results:

  • Individuals with higher baseline DPP4 activity exhibited elevated inflammatory markers, IGF-II/M6P receptor, and C-IMT.
  • Baseline DPP4 activity independently predicted increases in inflammatory markers, IGF-II/M6P receptor, and C-IMT over four years (P < 0.01).
  • The odds ratio for incident atherosclerosis was 3.17 (95% CI 1.33-7.58) in the highest vs. lowest DPP4 activity quartiles, with a 12.41% increase in atherosclerosis incidence attributed to DPP4 activity.

Conclusions:

  • DPP4 activity serves as a significant predictor of inflammation and atherosclerosis onset in apparently healthy Chinese individuals.
  • These findings highlight the proinflammatory role of DPP-4 in atherosclerosis pathogenesis, suggesting potential therapeutic targets.
Keywords:
AtherosclerosisC-IMTDPP4 activityInflammation

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
723
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.4K
Inflammation01:38

Inflammation

Overview
46.3K
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
656